The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 10564 participants.

Also called NCT01975389

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 10,564 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01975389
  • EudraCT 2013-002795-41
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01975389. Randomized; quadruple masking; primary purpose prevention. Start 2013-10-29 (actual); primary completion 2017-04-03 (actual). Results posted on 2018-06-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Acronym
SPIRE-2
Condition
Cardiovascular Disease
Intervention (Drug)
bococizumab (PF-04950615)
Intervention (Drug)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01975389
Content hash
204312a1c914dc151196dec6ca7eef06133474596d7f13f461f31786c83e8cee